Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 3/20 | 0.67 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.62 |
| ▸ | F2R | P25116 | 1/20 | 0.60 |
| ▸ | PTPRC | P08575 | 1/20 | 0.56 |
| ▸ | PTGES | O14684 | 3/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13709108 | 0.81 | RAB9A (0.50) | KCNK3KCNK9PTGS1RXFP1LMNA | |
| SCHEMBL5332281 | 0.81 | KCNK3 (0.75) | KCNK3KCNK9PTGS1RXFP1F2R | |
| SCHEMBL12764065 | 0.81 | KCNK3 (0.83) | KCNK3KCNK9PTGS1RXFP1F2R | |
| SCHEMBL8184566 | 0.80 | APOB (0.55) | PTGS1RXFP1LMNAGAAP2RX1 | |
| SCHEMBL2266591 | 0.80 | KMT2A (0.56) | AURKAAURKB | |
| SCHEMBL3766556 | 0.80 | KCNK3 (0.82) | KCNK3KCNK9PTGS1RXFP1F2R | |
| SCHEMBL18789745 | 0.79 | KCNK3 (0.65) | KCNK3KCNK9RXFP1F2RLMNA | |
| SCHEMBL21652194 | 0.78 | RXFP1 (0.73) | KCNK3KCNK9PTGS1RXFP1F2R | |
| SCHEMBL20641965 | 0.78 | KCNK3 (0.76) | KCNK3KCNK9PTGS1RXFP1F2R | |
| SCHEMBL2106763 | 0.78 | KCNK3 (0.76) | KCNK3KCNK9PTGS1RXFP1F2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | disclosed |
| WO-2009103778-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009103778-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | IL1B, LITAF, CYP11B1 | KCNK3 1692/4885KCNK9 1283/4885PTGS1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.